The neurodegenerative disease can be difficult to track in terms of remyelination, but certain agents can be monitored through ocular imaging to gauge efficacy.
Bausch + Lomb previewed a forthcoming product and pointed to company-funded research showing treatment effects possible after two, four and eight weeks of daily use.
This revision—accounting for reticular pseudodrusen and GA—shows that progression rates are substantially higher when using a more comprehensive approach.
A Danish study of 30,000 patients found increasing age, female sex and low comorbidity score were correlated with better diligence with eye drop treatment for up to 10 years.
The noninfectious form was helped by periocular and intraocular corticosteroids. Newer delivery methods have less evidence supporting their use due to the recency of their introduction.